Maze Therapeutics, Inc.MAZE stock score: 34/100
$32.43 · +3.94% · Scored Nov 19, 2026
- Technical
- 49
- Fundamental
- 30
- News
- —
The reading
Maze Therapeutics (MAZE) scores 34 out of 100, which reads bearish, higher than 9% of Healthcare stocks and 10% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 30, technicals 49.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Growth (Annual) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 46 and contrarian oscillators 53.
Since Aug 23, 2026 the composite has ranged from 34 to 50, and it is down 15 points over the period.
About Maze Therapeutics
Maze Therapeutics (MAZE) is a clinical-stage biotechnology company that develops oral small-molecule medicines for kidney and metabolic diseases, using human genetic data to choose drug targets. Its lead program, MZE829, is an oral inhibitor of the APOL1 protein being developed for APOL1-mediated kidney disease, a genetic form of chronic kidney disease that is more common among people of recent African ancestry. MZE829 has shown reductions in protein levels in the urine in a Phase two trial, and the company is preparing for later-stage studies. Its second program, MZE782, blocks the SLC6A19 transporter, which moves amino acids from the gut and kidney into the blood. Maze is testing MZE782 in phenylketonuria, an inherited disorder in which the amino acid phenylalanine builds up, and plans to study it in chronic kidney disease. The company has no approved products and funds its research mainly with cash raised from investors.
Maze faces competition from Vertex Pharmaceuticals, which is developing its own APOL1 inhibitor, and in phenylketonuria from BioMarin Pharmaceutical and PTC Therapeutics. Its edge rests on its genetics-driven approach to target selection, oral drugs that could treat broad patient groups and early clinical evidence in a disease with no approved targeted therapy. Investors who follow MAZE stock tend to watch further data from MZE829 and the design and start of a pivotal trial. Results from the MZE782 trial in phenylketonuria are closely followed. Feedback from regulators, cash runway, partnerships and the progress of Vertex’s competing program are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward MAZE’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
30Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Net income growth from the prior fiscal year to the latest.
EV/Revenue compares the whole company's value, debt included, with its sales.
5-year earnings growth evaluates long-term profit trajectory and consistency.
32 weighted scorers; 7 had no data today and are left out rather than counted as zero.
Technical · daily
50Pulling it up
Where the close sits against its 200-day EMA.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Holding it back
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Simple Moving Average (10-period) smooths price action over 10 periods.
Simple Moving Average (5-period) tracks the average price over the last 5 periods.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 44 | 1 |
| Daily | 50 | 3 |
| Weekly | 51 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 34 |
| Nov 18, 2026 | 34 |
| Nov 17, 2026 | 35 |
| Nov 16, 2026 | 35 |
| Nov 15, 2026 | 36 |
| Nov 14, 2026 | 36 |
| Nov 13, 2026 | 36 |
| Nov 12, 2026 | 36 |
| Nov 11, 2026 | 49 |
| Nov 10, 2026 | 48 |
| Nov 8, 2026 | 48 |
| Nov 7, 2026 | 48 |
| Nov 6, 2026 | 48 |
| Nov 5, 2026 | 47 |
| Nov 4, 2026 | 48 |
| Nov 3, 2026 | 46 |
| Nov 2, 2026 | 44 |
| Nov 1, 2026 | 44 |
| Oct 30, 2026 | 45 |
| Oct 29, 2026 | 47 |
| Oct 28, 2026 | 46 |
| Oct 27, 2026 | 46 |
| Oct 26, 2026 | 46 |
| Oct 25, 2026 | 46 |
| Oct 24, 2026 | 46 |
| Oct 23, 2026 | 46 |
| Oct 22, 2026 | 47 |
| Oct 21, 2026 | 48 |
| Oct 20, 2026 | 47 |
| Oct 19, 2026 | 45 |
| Oct 18, 2026 | 43 |
| Oct 17, 2026 | 43 |
| Oct 16, 2026 | 44 |
| Oct 15, 2026 | 42 |
| Oct 14, 2026 | 39 |
| Oct 13, 2026 | 41 |
| Oct 12, 2026 | 42 |
| Oct 11, 2026 | 42 |
| Oct 10, 2026 | 42 |
| Oct 9, 2026 | 42 |
| Oct 8, 2026 | 38 |
| Oct 7, 2026 | 39 |
| Oct 6, 2026 | 40 |
| Oct 5, 2026 | 39 |
| Oct 4, 2026 | 40 |
| Oct 3, 2026 | 40 |
| Oct 2, 2026 | 40 |
| Oct 1, 2026 | 41 |
| Sep 30, 2026 | 43 |
| Sep 29, 2026 | 43 |
| Sep 28, 2026 | 41 |
| Sep 27, 2026 | 40 |
| Sep 26, 2026 | 40 |
| Sep 25, 2026 | 39 |
| Sep 24, 2026 | 41 |
| Sep 23, 2026 | 43 |
| Sep 22, 2026 | 44 |
| Sep 21, 2026 | 35 |
| Sep 20, 2026 | 34 |
| Sep 19, 2026 | 34 |
| Sep 18, 2026 | 35 |
| Sep 17, 2026 | 35 |
| Sep 16, 2026 | 34 |
| Sep 15, 2026 | 36 |
| Sep 14, 2026 | 36 |
| Sep 13, 2026 | 37 |
| Sep 12, 2026 | 37 |
| Sep 11, 2026 | 37 |
| Sep 10, 2026 | 36 |
| Sep 9, 2026 | 39 |
| Sep 8, 2026 | 43 |
| Sep 7, 2026 | 42 |
| Sep 6, 2026 | 42 |
| Sep 5, 2026 | 42 |
| Sep 4, 2026 | 40 |
| Sep 3, 2026 | 40 |
| Sep 2, 2026 | 43 |
| Sep 1, 2026 | 42 |
| Aug 31, 2026 | 42 |
| Aug 30, 2026 | 44 |
| Aug 29, 2026 | 44 |
| Aug 28, 2026 | 44 |
| Aug 27, 2026 | 44 |
| Aug 26, 2026 | 48 |
| Aug 25, 2026 | 50 |
| Aug 24, 2026 | 48 |
| Aug 23, 2026 | 49 |
Key facts
- Market cap
- $1.8B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- —
- Risk grade (1–10)
- 8
- Next earnings
- Nov 9, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| REPL Replimune Group | $1.8B | 41 |
| STOK Stoke Therapeutics | $1.8B | 52 |
| RARE Ultragenyx Pharmaceutical | $1.8B | 47 |
| AGIO Agios Pharmaceuticals | $1.7B | 47 |
| ZBIO Zenas BioPharma | $1.7B | 31 |
| RXRX Recursion Pharmaceuticals | $1.7B | 45 |
Questions
What is MAZE's stock rating today?
MAZE scores 34/100 (Bearish) as of Nov 19, 2026: technical 49, fundamental 30. Scores are recomputed every night.
What does Maze Therapeutics do?
Maze Therapeutics (MAZE) is a clinical-stage biotechnology company that develops oral small-molecule medicines for kidney and metabolic diseases, using human genetic data to choose drug targets. Its lead program, MZE829, is an oral inhibitor of the APOL1 protein being developed for APOL1-mediated kidney disease, a genetic form of chronic kidney disease that is more common among people of recent African ancestry.
Is MAZE stock a buy?
The score is not a buy or sell recommendation. A 34 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the MAZE score calculated?
94 weighted scorers feed it today: 32 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/maze/"><img src="https://stocksscores.com/stocks/maze/badge.svg" alt="MAZE stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/maze/)